Geneva’s Federal Acquisition Program Manager, Genevieve Long, and Principal Investigator, Dr. Amy Shurtleff, are traveling to Chicago, IL to view the start of testing on newly developed Hantavirus DNA vaccines. Hantaviruses are carried by persistently-infected rodents and are transmitted by exposure to rodent excreta. At least four Hantaviruses are known to cause thousands of cases of hemorrhagic fever with renal syndrome (HFRS) each year and these vaccines in development are aimed at preventing two of them: Hantaan (HTNV) and Puumala (PUUV).
If these studies are successful, the Hantavirus DNA vaccines will move into Phase I human clinical trials for FDA approval and marketing.
Geneva welcomes the opportunity to connect with those who are not yet partnering with us! Please contact Geneva to learn more about our services and opportunities for collaboration.
FIND MORE news and events »